We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 96 results
  1. New drugs in the treatment of acute myeloid leukaemia

    Purpose of review

    In the past few years, research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to challenging...

    S. Kayser, Richard F. Schlenk in memo - Magazine of European Medical Oncology
    Article 01 June 2009
  2. Tc-99m-N-MPO: Novel cationic Tc-99m radiotracer for myocardial perfusion imaging

    Background . Technetium 99m-N-MPO ([Tc-99m-N(mpo)(PNP5)] + ) is a cationic Tc-99m nitrido complex. The objective of this study is to evaluate its...

    Young-Seung Kim, Jianjun Wang, ... Shuang Liu in Journal of Nuclear Cardiology
    Article 01 July 2008
  3. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice

    Purpose

    Previously, we studied the effect of co-administration of paclitaxel with the second generation ABCB1 (p-gp) modulator valspodar on the...

    Martina Hubensack, Christine Müller, ... Armin Buschauer in Journal of Cancer Research and Clinical Oncology
    Article 12 October 2007
  4. Expressions and clinicopathologic significance of five heat shock proteins in esophageal squamous cell carcinoma

    Objective

    To investigate the expressions of heat shock protein (hsp) 10, hsp27, hsp60, hsp70 and hsp90α in esophageal squamous cell carcinoma (ESCC)...

    Junhui Chen, Liming Chen, ... Liyan Xu in The Chinese-German Journal of Clinical Oncology
    Article 01 June 2007
  5. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)

    The importance of P-glycoprotein (P-gp) in the pharmacokinetics of amisulpride and the effects of a P-gp inhibitor cyclosporine A (CsA) was...

    U. Schmitt, A. Abou El-Ela, ... S. Härtter in Journal of Neural Transmission
    Article 27 October 2005
  6. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance

    cDNA microarray analysis is a highly useful tool for the classification of tumors and for prediction of patient prognosis to specific cancers based...

    David J. Villeneuve, Stacey L. Hembruff, ... Amadeo M. Parissenti in Breast Cancer Research and Treatment
    Article 02 December 2005
  7. Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells

    Anthracyclines are powerful cytotoxic agents, used as first-line treatment of leukemias and many other tumors, but host-tissue toxicity is their main...

    Michelutti Angela, Stocchi Raffaella, ... Damiani Daniela in Cancer Chemotherapy and Pharmacology
    Article 05 July 2005
  8. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice

    Purpose : To evaluate the pharmacological properties and the possible therapeutic applications of a series of synthetic marine natural product...

    Ting-Chao Chou, Yongbiao Guan, ... Dale L. Boger in Cancer Chemotherapy and Pharmacology
    Article 04 May 2005
  9. Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain

    The permeability of the blood–brain barrier (BBB) is one of the factors determining the bioavailability of drugs in the brain. The BBB only allows...

    Philip H. Elsinga, N. Harry Hendrikse, ... Willem Vaalburg in Molecular Imaging and Biology
    Article 01 January 2005
  10. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

    P-glycoprotein inhibitors can increase the oral bioavailability of paclitaxel. We have now explored the mechanisms that determine the efficacy of...

    Heleen A. Bardelmeijer, Mariët Ouwehand, ... Olaf van Tellingen in Investigational New Drugs
    Article 01 August 2004
  11. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2

    Purpose

    Intrinsic P-glycoprotein (P-gp) expression in the gut limits paclitaxel uptake and, thus, its bioavailability when administered orally....

    Candice Jamois, Emmanuelle Comets, ... Laurence Bonhomme-Faivre in Cancer Chemotherapy and Pharmacology
    Article 16 September 2004
  12. Cross-Resistance Studies of Isogenic Drug-Resistant Breast Tumor Cell Lines Support Recent Clinical Evidence Suggesting that Sensitivity to Paclitaxel may be Strongly Compromised by Prior Doxorubicin Exposure

    Less than half of breast cancer patients respond to second-line chemotherapy with paclitaxel after failing treatment with anthracyclines such as...

    Baoqing Guo, David J. Villeneuve, ... Amadeo M. Parissenti in Breast Cancer Research and Treatment
    Article 01 May 2004
  13. Experimental study on the preventive mechanism of salviae miltiorrhizae against atherosclerosis in rabbits models

    The preventive mechanism of salviae miltiorrhizae (SM) against experimental atherosclerosis (AS) in rabbits models was investigated. The experimental...

    LI Shusheng, Wan Lei in Current Medical Science
    Article 01 June 2004
  14. Effect of valspodar on the pharmacokinetics of unbound paclitaxel

    The aim of this multicenter study was to determine whether valspodar (Amdray™; code designation, SDZ PSC 833), a potent P-glycoprotein (P-gp)...

    Albert J. ten Tije, Timothy W. Synold, ... Alex Sparreboom in Investigational New Drugs
    Article 01 August 2003
  15. Potent Killing of Paclitaxel- and Doxorubicin-resistant Breast Cancer Cells by Calphostin C Accompanied by Cytoplasmic Vacuolization

    Drug resistance is a major impediment to the successful treatment of breast cancer using chemotherapy. The photoactivatable drug calphostin C has...

    Baoqing Guo, Stacey L. Hembruff, ... Amadeo M. Parissenti in Breast Cancer Research and Treatment
    Article 01 November 2003
  16. The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice

    Circumvention of chemoresistance in cancer may involve several modulator drugs with high affinity for the multidrug transporter P-glycoprotein (Pgp),...

    G Lehne, DR Sørensen, ... OPF Clausen in Leukemia
    Article 26 November 2002
  17. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

    Abstract

    Purpose. To develop a population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of zosuquidar.3HCl, a potent...

    Sophie Callies, Dinesh P. de Alwis, ... Leon Aarons in Cancer Chemotherapy and Pharmacology
    Article 01 February 2003
  18. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts

    Abstract

    Purpose. We have recently identified a deoxycytidine nucleoside analogue, troxacitabine (β- L -dioxolane cytidine, Troxatyl; Shire BioChem),...

    Henriette Gourdeau, Philippe Genne, ... Giorgio Attardo in Cancer Chemotherapy and Pharmacology
    Article 01 December 2002
  19. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel

    Purpose: Recent studies in humans and mice have demonstrated that intestinal P-glycoprotein plays a causative role in the limited absorption of...

    Yoshimitsu Kimura, Jun Aoki, ... Osamu Nakanishi in Cancer Chemotherapy and Pharmacology
    Article 01 April 2002
Did you find what you were looking for? Share feedback.